A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Inclusion Criteria: * 1\. Part I: Age 18 -65 years old; Part II: Aged ≥ 18 years old, both male and female. * 2\. Previously untreated patients with CD20-positive DLBCL diagnoses by 2022 WHO. * 3\. Measurable disease of at least 15mm (node)/10mm (extranodal). * 4\. ECOG performance status 0-2. * 5\. International Prognostic Index (IPI) score of 2-5. * 6\. Estimated survival time ≥6 months. * 7\. Having sufficient organ function. * 8\. Female and male patients of childbearing age and their spouses are willing to carry out adequate contraception throughout the study period, and female patients of childbearing age must have negative serum pregnancy test within 7 days before the first administration. * 9\. Patients voluntarily agree to participate in the study and to sign the informed consent form. Exclusion Criteria: * 1\. Contraindication to any of the individual components of study drugs, including prior receipt of xenoproteins, biological agents. * 2\. Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load; Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load; Human immunodeficiency virus (HIV) seropositive. * 3\. Clinically apparent central nervous system (CNS) lymphoma. * 4\. Patient has ≥ Grade 2 peripheral neuropathy. * 5\. Investigator-assessed diabetes uncontrolled by drug t…